162 related articles for article (PubMed ID: 16351191)
1. Nanotechnology-based photodynamic therapy for neovascular disease using a supramolecular nanocarrier loaded with a dendritic photosensitizer.
Ideta R; Tasaka F; Jang WD; Nishiyama N; Zhang GD; Harada A; Yanagi Y; Tamaki Y; Aida T; Kataoka K
Nano Lett; 2005 Dec; 5(12):2426-31. PubMed ID: 16351191
[TBL] [Abstract][Full Text] [Related]
2. [Novel approach for management of age-related macular degeneration--antiangiogenic therapy and retinal regenerative therapy].
Tamaki Y
Nippon Ganka Gakkai Zasshi; 2007 Mar; 111(3):232-68; discussion 269. PubMed ID: 17402564
[TBL] [Abstract][Full Text] [Related]
3. Prospects for nanomedicine in treating age-related macular degeneration.
Tamaki Y
Nanomedicine (Lond); 2009 Apr; 4(3):341-52. PubMed ID: 19331541
[TBL] [Abstract][Full Text] [Related]
4. Vascular-targeted photodynamic therapy in the treatment of neovascular age-related macular degeneration: Clinical perspectives.
Kawczyk-Krupka A; Bugaj AM; Potempa M; Wasilewska K; Latos W; Sieroń A
Photodiagnosis Photodyn Ther; 2015 Jun; 12(2):161-75. PubMed ID: 25843911
[TBL] [Abstract][Full Text] [Related]
5. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
Spielberg L; Leys A
Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
[TBL] [Abstract][Full Text] [Related]
6. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2.
Renno RZ; Terada Y; Haddadin MJ; Michaud NA; Gragoudas ES; Miller JW
Arch Ophthalmol; 2004 Jul; 122(7):1002-11. PubMed ID: 15249365
[TBL] [Abstract][Full Text] [Related]
7. Photosensitizer delivery for photodynamic therapy of choroidal neovascularization.
Renno RZ; Miller JW
Adv Drug Deliv Rev; 2001 Oct; 52(1):63-78. PubMed ID: 11672876
[TBL] [Abstract][Full Text] [Related]
8. Liposomal hypocrellin B as a potential photosensitizer for age-related macular degeneration: pharmacokinetics, photodynamic efficacy, and skin phototoxicity in vivo.
Li T; Hou X; Deng H; Zhao J; Huang N; Zeng J; Chen H; Gu Y
Photochem Photobiol Sci; 2015 May; 14(5):972-81. PubMed ID: 25793654
[TBL] [Abstract][Full Text] [Related]
9. Ocular photodynamic therapy--standard applications and new indications (part 1). Review of the literature and personal experience.
Mennel S; Barbazetto I; Meyer CH; Peter S; Stur M
Ophthalmologica; 2007; 221(4):216-26. PubMed ID: 17579286
[TBL] [Abstract][Full Text] [Related]
10. Photodynamic therapy with verteporfin for anterior segment neovascularizations in neovascular glaucoma.
Parodi MB; Iacono P
Am J Ophthalmol; 2004 Jul; 138(1):157-8. PubMed ID: 15234305
[TBL] [Abstract][Full Text] [Related]
11. Treatment of macular degeneration (a controlled case).
Soucek P; Cihelková I
Neuro Endocrinol Lett; 2002 Aug; 23(4):370-2. PubMed ID: 12195243
[TBL] [Abstract][Full Text] [Related]
12. Selective occlusion of choroidal neovascularization by photodynamic therapy with a water-soluble photosensitizer, ATX-S10.
Obana A; Gohto Y; Kaneda K; Nakajima S; Takemura T; Miki T
Lasers Surg Med; 1999; 24(3):209-22. PubMed ID: 10229152
[TBL] [Abstract][Full Text] [Related]
13. Real-time vascular imaging and photodynamic therapy efficacy with micelle-nanocarrier delivery of chlorin e6 to the microenvironment of melanoma.
Lee CH; Lai PS; Lu YP; Chen HY; Chai CY; Tsai RK; Fang KT; Tsai MH; Hsu CY; Hung CC; Wu DC; Yu HS; Chang CH; Tsai DP
J Dermatol Sci; 2015 Nov; 80(2):124-32. PubMed ID: 26360010
[TBL] [Abstract][Full Text] [Related]
14. Fluorinated polymeric micelles to overcome hypoxia and enhance photodynamic cancer therapy.
Wang Q; Li JM; Yu H; Deng K; Zhou W; Wang CX; Zhang Y; Li KH; Zhuo RX; Huang SW
Biomater Sci; 2018 Oct; 6(11):3096-3107. PubMed ID: 30306153
[TBL] [Abstract][Full Text] [Related]
15. Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys.
Kramer M; Miller JW; Michaud N; Moulton RS; Hasan T; Flotte TJ; Gragoudas ES
Ophthalmology; 1996 Mar; 103(3):427-38. PubMed ID: 8600419
[TBL] [Abstract][Full Text] [Related]
16. Predictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration.
Parmeggiani F; Gemmati D; Costagliola C; Sebastiani A; Incorvaia C
Pharmacogenomics; 2009 Jan; 10(1):81-95. PubMed ID: 19102718
[TBL] [Abstract][Full Text] [Related]
17. Principles of treatment of choroidal neovascularization with photodynamic therapy in age-related macular degeneration.
Donati G; Kapetanios AD; Pournaras CJ
Semin Ophthalmol; 1999 Mar; 14(1):2-10. PubMed ID: 10790570
[TBL] [Abstract][Full Text] [Related]
18. Factor VII-verteporfin for targeted photodynamic therapy in a rat model of choroidal neovascularization.
Lu F; Hu Z; Sinard J; Garen A; Adelman RA
Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):3890-6. PubMed ID: 19357351
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration.
Schmidt-Erfurth U; Hasan T
Surv Ophthalmol; 2000; 45(3):195-214. PubMed ID: 11094244
[TBL] [Abstract][Full Text] [Related]
20. Singlet oxygen-responsive micelles for enhanced photodynamic therapy.
Li X; Gao M; Xin K; Zhang L; Ding D; Kong D; Wang Z; Shi Y; Kiessling F; Lammers T; Cheng J; Zhao Y
J Control Release; 2017 Aug; 260():12-21. PubMed ID: 28527734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
